Details for New Drug Application (NDA): 207754
✉ Email this page to a colleague
The generic ingredient in FULVESTRANT is fulvestrant. There are twelve drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the fulvestrant profile page.
Summary for 207754
| Tradename: | FULVESTRANT |
| Applicant: | Glenmark Pharms Inc |
| Ingredient: | fulvestrant |
| Patents: | 0 |
Pharmacology for NDA: 207754
| Mechanism of Action | Estrogen Receptor Antagonists Selective Estrogen Receptor Modulators |
Suppliers and Packaging for NDA: 207754
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FULVESTRANT | fulvestrant | SOLUTION;INTRAMUSCULAR | 207754 | ANDA | GLENMARK PHARMACEUTICALS INC., USA | 68462-317 | 68462-317-32 | 2 SYRINGE, GLASS in 1 CARTON (68462-317-32) / 5 mL in 1 SYRINGE, GLASS (68462-317-40) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAMUSCULAR | Strength | 250MG/5ML (50MG/ML) | ||||
| Approval Date: | Aug 22, 2019 | TE: | AO | RLD: | No | ||||
Complete Access Available with Subscription
